A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy

BACKGROUND: Recent developments improved outcomes in patients with autoimmune diseases. Biologics were approved as first-line treatment in selected naïve patients with plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortesi, Paolo Angelo, Fornari, Carla, Gisondi, Paolo, Iannone, Florenzo, Antonazzo, Ippazio Cosimo, Aloisi, Elisabetta, Fiocchi, Martina, Ritrovato, Daniela, Mantovani, Lorenzo Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169960/
https://www.ncbi.nlm.nih.gov/pubmed/36929647
http://dx.doi.org/10.1007/s41669-023-00404-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169960/
https://www.ncbi.nlm.nih.gov/pubmed/36929647
http://dx.doi.org/10.1007/s41669-023-00404-3

Ejemplares similares